CLOPIXOL TABLETS 10MG

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

ZUCLOPENTHIXOL (ZUCLOPENTHIXOL HYDROCHLORIDE)

Sẵn có từ:

LUNDBECK CANADA INC

Mã ATC:

N05AF05

INN (Tên quốc tế):

ZUCLOPENTHIXOL

Liều dùng:

10MG

Dạng dược phẩm:

TABLET

Thành phần:

ZUCLOPENTHIXOL (ZUCLOPENTHIXOL HYDROCHLORIDE) 10MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

100

Loại thuốc theo toa:

Prescription

Khu trị liệu:

THIOXANTHENES

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0127600001; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

1997-01-30

Đặc tính sản phẩm

_ _
_ _
_Page 1 of 34_
PRODUCT MONOGRAPH
Pr
CLOPIXOL
®
Zuclopenthixol Tablets Lundbeck Std.
(10 mg and 25 mg zuclopenthixol as zuclopenthixol hydrochloride)
Lundbeck standard
Pr
CLOPIXOL-ACUPHASE
®
50 mg/mL Zuclopenthixol Intramuscular Injection
(45.25 mg/mL zuclopenthixol as zuclopenthixol acetate)
Lundbeck standard
Pr
CLOPIXOL
® DEPOT
200 mg/mL Zuclopenthixol Intramuscular Injection
(144.4 mg/mL zuclopenthixol as zuclopenthixol decanoate)
Lundbeck standard
ANTIPSYCHOTIC AGENT
Lundbeck Canada Inc.
1000 De la Gauchetière Street West
Suite 500
Montréal, QC
H3B 4W5
Date of Revision:
08 April 2014
Submission Control No : 171198
_ _
_ _
_Page 2 of 34_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
............................